News
Article
Author(s):
In case you missed it, this week we had news about the FDA approval of deuruxolitinib for severe alopecia in adults, new nonmelanoma guidelines from the Dermatology Association of Radiation Therapy, Arcutis' submitted sNDA for roflumilast foam for scalp and body psoriasis, and more.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Robert Posnick, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving hyperpigmentation and alopecia areata.
Researchers examined the role of diabetes and glycemic profile in the risk of development of vitiligo in a Mendelian randomization study.
The guidelines for BCC and SCC treatment with IGSRT detail diagnosis, staging, contraindications, protocols, and emphasize the essential role of a multidisciplinary team.
Oral dimethyl fumarate improved all disease classification criteria for plaque psoriasis, showing significant betterment of severity and quality of life.
Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab.
In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on key career mentors.
Explore various elements that can go into a comprehensive insurance benefits package for dermatology practice employees.
The submission to the FDA is supported by positive results from the ARRECTOR phase 3 trial.
A recent review investigated all known information between skin conditions and sleep disorders, finding a bidirectional influence between them.
Researchers noted that many dermatologists face mild, non-life-threatening complications during procedures, yet must be prepared for emergencies.
A recent study examined skin manifestations and SS from a dermatological perspective.
Renata Block, MMS, PA-C, interviews dermatology clinicians and the Melanoma Research Foundation CEO at the Chicago SPF Fest.
Of those who have reported latex allergy, approximately 75% are health care workers. What should practice owners and managers need to consider legally?
A recent study saw a “significant” decrease in allergen-specific IgE levels over a 1-year period of dupilumab therapy in children with atopic dermatitis.
Margins < 1 mm also do not increase the risk of cutaneous squamous cell carcinoma recurrence risk if the galea aponeurotica is not involved.
Social media misinformation related to acne vulgaris may require clinician intervention when discussing treatment with patients.
Researchers behind the phase 3 studies gave pearls into the study methods, results, and what is up next.
Data from numerous studies identified fluorouracil 5% as ranking the most effective across 3 outcomes.
Compared to a stapling device, Xkin reduced scarring, pain, and infection risk more effectively in surgical and trauma wounds.
A systematic review of 31 studies found that patients with EBA responded well to rituximab with few adverse effects.
The study highlights the need for personalized treatments, suggesting that this combination therapy is most beneficial when tailored to individual risk profiles.
In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on how the publication has impacted their practice.
Combining electrocoagulation with pharmacotherapy significantly reduced keloid scar volume by inhibiting collagen deposition, angiogenesis, and cell proliferation.
Along with the approval, Sun Pharma is introducing an access program to assist eligible patients in starting and adhering to the treatment.
The lotion effectively rebalanced the microbiota, reduced erythema and desquamation, and improved acne severity.
A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.
Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.
Investigators looked into pollutant-induced disruption of the skin barrier, increased transepidermal water loss, and heightened inflammatory responses.